subject area of
- A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck Conferences
- Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial Journal Articles
- Discovery of potent antiviral (HSV-1) quinazolinones and initial structure-activity relationship studies Journal Articles
- Growth inhibition of prostate cancer xenografts by halofuginone*† Journal Articles
- High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells Journal Articles
- INHIBITION OF WILMS TUMOR XENOGRAFT PROGRESSION BY HALOFUGINONE IS ACCOMPANIED BY ACTIVATION OF WT-1 GENE EXPRESSION Conferences
- Inhibition of fibroblast to myofibroblast transition by halofuginone contributes to the chemotherapy-mediated antitumoral effect Journal Articles
- One-pot, multicomponent synthesis of 2,3-disubstituted quinazolin-ones with potent and selective activity against Toxoplasma gondii Journal Articles
- The clinical antiprotozoal drug halofuginone promotes weight loss by elevating GDF15 and FGF21. Journal Articles